Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, People's Republic of China.
Stem Cell Rev Rep. 2013 Dec;9(6):806-13. doi: 10.1007/s12015-013-9457-0.
Immune rejection hinders the application of human embryonic stem cells (hESCs) in transplantation therapy. Human leukocyte antigens (HLAs) on the cell surface are the major cause of graft rejection. In this study, we generated HLA class I-deficient hESCs via disruption of beta 2-microglobulin (β2m), the light chain of HLA Class I. We found that HLA class I proteins were not present on the cell surface of β2m-null hESCs. These cells showed the same pluripotency as wildtype hESCs and demonstrated hypoimmunogenicity. Thus, HLA class I-deficient hESCs might serve as an unlimited cell source for the generation of universally compatible "off-the-shelf" cell grafts, tissues or organs in the future.
免疫排斥阻碍了人类胚胎干细胞（hESCs）在移植治疗中的应用。细胞表面上的人类白细胞抗原（HLAs）是移植物排斥的主要原因。在这项研究中，我们通过破坏β2-微球蛋白（β2m）（HLA I 类的轻链）生成了 HLA I 类缺陷的 hESCs。我们发现，β2m 缺失的 hESCs 细胞表面不存在 HLA I 类蛋白。这些细胞显示出与野生型 hESCs 相同的多能性，并表现出低免疫原性。因此，HLA I 类缺陷的 hESCs 将来可能成为生成普遍相容的“现成”细胞移植物、组织或器官的无限细胞来源。
